Molecular analysis of holocarboxylase synthetase deficiency: A missense mutation and a single base deletion are predominant in Japanese patients
Aoki Y, Suzuki Y, Sakamoto O et al. Molecular analysis of holocarboxylase synthetase deficiency: a missense mutation and a single base deletion are predominant in Japanese patients. Biochim Biophys Acta 1995; 1272: 168-174
Clustering of mutations in the biotin-binding region of holocarboxylase synthetase in biotin-responsive multiple carboxylase deficiency
Dupuis L, Leon-Del-Rio A, Leclerc D et al. Clustering of mutations in the biotin-binding region of holocarboxylase synthetase in biotin-responsive multiple carboxylase deficiency. Hum Mol Genet 1996; 5: 1011-1016
Cloning of the holocarboxylase synthetase cDNA and identification of mutations prevalent in Japanese HCS-deficient patients
Narisawa K, Suzuki Y, Aoki Y. Cloning of the holocarboxylase synthetase cDNA and identification of mutations prevalent in Japanese HCS-deficient patients. Nippon Rinsho 1996; 54: 259-267
Mutational hotspot in the human biotinidase gene causes profound biotinidase deficiency
Pomponio RJ, Reynolds TR, Cole H et al. Mutational hotspot in the human biotinidase gene causes profound biotinidase deficiency. Nat Genet 1995; 11: 96-98
Acute neurologic dysfunction associated with destructive lesions of the basal ganglia: A benign form of infantile bilateral striatal necrosis
Roig M, Macaya A, Munell F et al. Acute neurologic dysfunction associated with destructive lesions of the basal ganglia: a benign form of infantile bilateral striatal necrosis. J Pediatr 1990; 117: 578-581
Familial infantile bilateral striatal necrosis: Clinical features and response to biotin treatment
Straussberg R, Shorer Z, Weitz R et al. Familial infantile bilateral striatal necrosis: clinical features and response to biotin treatment. Neurology 2002; 59: 983-989
Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3
Zeng WQ, Al-Yamani E, Acierno JS Jr et al. Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3. Am J Hum Genet 2005; 77: 16-26